Papert, Susanne

[["dc.bibliographiccitation.firstpage","1127"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1133"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:22:22Z"],["dc.date.available","2018-11-07T10:22:22Z"],["dc.date.issued","2017"],["dc.description.abstract","Graft-versus-host disease (GvHD) still belongs to the major challenges after allogeneic hematopoietic stem cell transplantation (HSCT). Immune-suppressive therapy against GvHD is a double-edged sword due to risk of infections and relapse. The ability to adapt prophylactic treatment according to the probability of severe GvHD would be an essential advantage for the patients. We analyzed different biomarkers for their potential to predict the development of GvHD in 28 patients who underwent allogeneic HSCT. Blood was taken once directly after hematopoietic engraftment. In this study, patients were monitored for 12 months after HSCT for the occurrence of acute GvHD or acute/chronic GvHD overlap syndrome. Soluble IL-2 receptor and CD4/CD8 T cell ratio were independently associated with the occurrence of GvHD in the observation period. However, the largest area under the receiver operating characteristic curve with 0.90 was observed when a 5-parameter biomarker score based on CD4(+) T cells, CD8(+) T cells, CD19(-) CD21(+) precursor B cells, CD4/CD8 T cell ratio, and soluble IL-2 receptor was used to predict GvHD. In addition, CD8(+) T cell levels above 2.3% of all mononuclear cells after engraftment may predict relapse-free survival at least for 12 months. In summary, we found a new biomarker panel for prediction of GvHD which is featured by established laboratory assays and high statistical significance. In order to introduce the biomarker panel into routine clinical protocols, we suggest performing a larger multi-center study."],["dc.identifier.doi","10.1007/s00277-017-2999-5"],["dc.identifier.isi","000403078900008"],["dc.identifier.pmid","28447161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42255"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HLA"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:23:29Z"],["dc.date.available","2018-11-07T10:23:29Z"],["dc.date.issued","2017"],["dc.format.extent","345"],["dc.identifier.isi","000400973300016"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42465"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.publisher.place","Hoboken"],["dc.relation.issn","2059-2310"],["dc.relation.issn","2059-2302"],["dc.title","AN ALTERNATIVE SETUP FOR EXTRACORPOREAL PHOTOPHERESIS: 8-METHOXYPSORALEN AND UVA-TREATED LEUKOCYTES FROM ALLOGENEIC DONORS IMPROVE GRAFT VERSUS HOST DISEASE IN MICE"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HLA"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:23:29Z"],["dc.date.available","2018-11-07T10:23:29Z"],["dc.date.issued","2017"],["dc.format.extent","362"],["dc.identifier.isi","000400973300051"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42466"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.publisher.place","Hoboken"],["dc.relation.issn","2059-2310"],["dc.relation.issn","2059-2302"],["dc.title","SCREENING FOR A BIOMARKER PANEL FOR PREDICTION OF GRAFT VERSUS HOST DISEASE IN HUMANS"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","803"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Vox Sanguinis"],["dc.bibliographiccitation.lastpage","810"],["dc.bibliographiccitation.volume","113"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Reichardt, Holger M."],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias J."],["dc.date.accessioned","2020-12-10T18:36:32Z"],["dc.date.available","2020-12-10T18:36:32Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1111/vox.12723"],["dc.identifier.issn","0042-9007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76662"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","An alternative for extracorporeal photopheresis: 8-methoxypsoralen and UVA-treated leucocytes from allogeneic donors improve graft-versus-host disease in mice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","jog.15348"],["dc.bibliographiccitation.firstpage","2571"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Journal of Obstetrics and Gynaecology Research"],["dc.bibliographiccitation.lastpage","2582"],["dc.bibliographiccitation.volume","48"],["dc.contributor.affiliation","Eidizadeh, Abass; 1\r\nInstitute for Clinical Chemistry/Interdisciplinary UMG Laboratory\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Papert, Susanne; 2\r\nDepartment of Transfusion Medicine\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Valk, Jakob; 2\r\nDepartment of Transfusion Medicine\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Pollok‐Kopp, Beatrix; 2\r\nDepartment of Transfusion Medicine\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Goldmann, Monika; 2\r\nDepartment of Transfusion Medicine\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Riggert, Joachim; 2\r\nDepartment of Transfusion Medicine\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Moltrecht, Rüdiger; 3\r\nMVZ Göttingen\r\nGöttingen Germany"],["dc.contributor.author","Eidizadeh, Abass"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Valk, Jakob"],["dc.contributor.author","Pollok‐Kopp, Beatrix"],["dc.contributor.author","Goldmann, Monika"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Moltrecht, Rüdiger"],["dc.contributor.author","Legler, Tobias J."],["dc.date.accessioned","2022-11-28T08:47:54Z"],["dc.date.available","2022-11-28T08:47:54Z"],["dc.date.issued","2022-07-01"],["dc.date.updated","2022-11-27T10:10:45Z"],["dc.description.abstract","Abstract\r\n\r\nAim\r\nUnexplained infertility is a major burden for couples who want to have children. Lymphocyte immunotherapy (LIT) could be a therapeutic help for these couples. Although LIT has been carried out for decades, the data on the success of therapy are still controversial and there is hardly information on possible adverse drug reactions.\r\n\r\n\r\nMethods\r\nIn this study, we used a questionnaire to determine the frequency of local and systemic adverse drug reactions in our patients who were treated with LIT between 2017 and 2020 (n = 302). In addition, we asked about pregnancies and/or live births after LIT in a 2‐year follow‐up (n = 140).\r\n\r\n\r\nResults\r\nMost of the patients reported the occurrence of mild local adverse drug reactions in a period of less than 4 weeks: Over 75% reported moderate erythema, itching or swelling, over 10% erythema, itching or swelling as more pronounced adverse drug reaction. Blistering was specified in 10% of the cases. Serious adverse drug reactions or adverse events were not described. In the follow‐up, 69% of our patients stated a pregnancy after LIT, and 50% a life birth.\r\n\r\n\r\nConclusions\r\nOverall, LIT represents a well‐tolerated therapy for couples with unexplained infertility, however, more evidence is needed on the benefits."],["dc.identifier.doi","10.1111/jog.15348"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/117279"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.publisher","John Wiley & Sons Australia, Ltd"],["dc.relation.eissn","1447-0756"],["dc.relation.issn","1341-8076"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.rights.uri","http://creativecommons.org/licenses/by-nc-nd/4.0/"],["dc.title","Adverse drug reactions following lymphocyte immunotherapy for the treatment of infertility: A retrospective study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]